Monopar Therapeutics (MNPR) Total Current Liabilities (2016 - 2025)

Monopar Therapeutics has disclosed Total Current Liabilities across 10 years of filings, most recently posting $2.7 million for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $2.7 million, down 47.94% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.7 million (down 47.94% YoY), and the FY2025 annual result was $2.7 million, down 47.94% from the prior year.
• Total Current Liabilities came in at $2.7 million for Q4 2025 at Monopar Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $5.3 million in Q4 2024 to a low of $806272.0 in Q1 2021.
• The 5-year median for Total Current Liabilities is $2.1 million (2022), against an average of $2.3 million.
• Across the five-year window, Total Current Liabilities jumped 198.98% in 2024 and sank 47.94% in 2025, its largest moves.
• Monopar Therapeutics' Total Current Liabilities stood at $1.6 million in 2021, then surged by 97.96% to $3.1 million in 2022, then tumbled by 43.83% to $1.8 million in 2023, then jumped by 198.98% to $5.3 million in 2024, then tumbled by 47.94% to $2.7 million in 2025.
• The last three Total Current Liabilities figures came in at $2.7 million (Q4 2025), $2.6 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.